🇺🇸 Ametop in United States

33 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 33

Most-reported reactions

1. Lip Swelling — 6 reports (18.18%)
2. Eyelid Oedema — 5 reports (15.15%)
3. Pyrexia — 4 reports (12.12%)
4. Deep Vein Thrombosis — 3 reports (9.09%)
5. Diarrhoea — 3 reports (9.09%)
6. Ejection Fraction Decreased — 3 reports (9.09%)
7. Mucosal Inflammation — 3 reports (9.09%)
8. Acute Kidney Injury — 2 reports (6.06%)
9. Device Dislocation — 2 reports (6.06%)
10. Hypoacusis — 2 reports (6.06%)

Source database →

Frequently asked questions

Is Ametop approved in United States?

Ametop does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Ametop in United States?

University of British Columbia is the originator. The local marketing authorisation holder may differ — check the official source linked above.